GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LungLife AI Inc (LSE:LLAI) » Definitions » NonCurrent Deferred Liabilities

LungLife AI (LSE:LLAI) NonCurrent Deferred Liabilities : £0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LungLife AI NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

LungLife AI's non-current deferred liabilities for the quarter that ended in Dec. 2023 was £0.00 Mil.

LungLife AI NonCurrent Deferred Liabilities Historical Data

The historical data trend for LungLife AI's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LungLife AI NonCurrent Deferred Liabilities Chart

LungLife AI Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial - - - - -

LungLife AI Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LungLife AI NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of LungLife AI's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


LungLife AI (LSE:LLAI) Business Description

Traded in Other Exchanges
N/A
Address
2545 W. Hillcrest Drive, Suite 140, Thousand Oaks, CA, USA, 91320
LungLife AI Inc is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence. Its LungLB Test is a blood-based tool developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer.

LungLife AI (LSE:LLAI) Headlines

No Headlines